Priority review voucher updates: Who's won PRVs, who's bought them, and how much they're selling for
The system by which the FDA awards biopharma companies with priority review vouchers for new approvals of treatments for neglected tropical diseases, rare pediatric diseases and medical countermeasures continues to thrive, more than a decade after it began.
The vouchers, known as PRVs, can either be sold on the open market or used by the sponsor to shorten another new drug’s FDA review from 10 months to 6 months. Despite concerns that more PRVs would inevitably diminish their worth, they continue to fetch about $100 million each, even as more than a dozen PRVs still haven’t been used or sold (see below).
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.